ELECT: A phase 3 study of efficacy and safety of lanreotide autogel/depot (LAN) treatment for carcinoid syndrome in patients with neuroendocrine tumors (NETs)

被引：11
|
作者：
Vinik, Aaron
Wolin, Edward M.
Audry, Helene
Gomez-Panzani, Edda L.
机构：
[1] Eastern Virginia Med Sch, Norfolk, VA 23501 USA
[2] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA
[3] Ipsen, Boulougne Billancourt, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 03期
关键词：
D O I：
10.1200/jco.2014.32.3_suppl.268
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
268
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Lanreotide Autogel/ Depot (LAN) in Lung Neuroendocrine Tumours (NETs): The Randomized, Double-Blind, Placebo (PBO)-Controlled, International Phase 3 SPINET Study
    Reidy-Lagunes, D.
    Kulke, M. H.
    Wolin, E. M.
    Singh, S.
    Ferone, D.
    Hoersch, D.
    Mirakhur, B.
    Hoffmanns, P.
    Houchard, A.
    Caplin, M.
    Baudin, E.
    [J]. NEUROENDOCRINOLOGY, 2017, 105 : 209 - 209
  • [32] Patient-Reported Satisfaction with Diarrhea Control Associated with Lanreotide Autogel/Depot (LAN) Treatment for Carcinoid Syndrome (CS) Is High in Gastroenteropancreatic Neuroendocrine Tumor (NET) Patients
    Ruszniewski, Philippe
    Caplin, Marlyn E.
    Valle, Juan
    Lombard-Bohas, Catherine
    Poston, Graeme
    Perros, Petros
    Holubec, Lubo
    Delle Fave, Gianfranco
    Smith, Denis
    Niccoli, Patricia
    Maisonobe, Pascal
    Massien, Christine
    [J]. ENDOCRINE REVIEWS, 2014, 35 (03)
  • [33] Lanreotide depot/autogel (LAN) in patients with neuroendocrine tumors (NETs) aged ≤65 vs. >65 years: Subgroup analyses from the CLARINET study.
    Dasari, A.
    Phan, Alexandria T.
    Caplin, Martyn E.
    Pavel, Marianne E.
    Cwikla, Jaroslaw B.
    Raderer, Markus
    Sedlackova, Eva
    Cadiot, Guillaume
    Wolin, Edward M.
    Capdevila, Jaume
    Wall, Lucy
    Rindi, Guido
    Langley, Alison
    Gomez-Panzani, Edda
    Ruszniewski, Philippe B.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [34] Prognostic factors for progression-free survival (PFS) in CLARINET study of lanreotide depot/autogel (LAN) vs placebo (PBO) in neuroendocrine tumors (NETs).
    Wolin, Edward M.
    Caplin, Martyn E.
    Pavel, Marianne E.
    Cwikla, Jaroslaw B.
    Phan, Alexandria T.
    Raderer, Markus
    Sedlackova, Eva
    Cadiot, Guillaume
    Capdevila, Jaume
    Wall, Lucy
    Rindi, Guido
    Langley, Alison
    Gomez-Panzani, Edda
    Ruszniewski, Philippe B.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [35] Efficacy and Safety of Lanreotide Autogel and Temozolomide Combination Therapy in Progressive Thoracic Neuroendocrine Tumors (carcinoid): Results from the Phase 2 ATLANT Study
    Ferolla, Piero
    Berruti, Alfredo
    Spada, Francesca
    Brizzi, Maria Pia
    Ibrahim, Toni
    Marconcini, Riccardo
    Giuffrida, Dario
    Amoroso, Vito
    La Salvia, Anna
    Vaccaro, Vanja
    Faggiano, Antongiulio
    Colao, Annamaria
    Volante, Marco
    Ghizzoni, Simona
    Mazzanti, Paola
    Houchard, Aude
    Fazio, Nicola
    [J]. NEUROENDOCRINOLOGY, 2023, 113 (03) : 332 - 342
  • [36] Lanreotide Depot/Autogel in Neuroendocrine Tumors: Subgroup Analyses From the CLARINET Study
    不详
    [J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2015, 13 (08) : 6 - 8
  • [37] Tumor Response in the CLARINET Study of Lanreotide Depot/Autogel vs Placebo in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
    不详
    [J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2016, 14 (03) : 11 - 12
  • [38] SPINET: A Randomized, Double-blind, Placebo-controlled Phase III Study of Lanreotide Autogel/Depot (LAN) in Patients with Advanced Lung Neuroendocrine Tumors
    Reidy-Lagunes, Diane
    Kulke, Matthew
    Wolin, Edward
    Singh, Simron
    Ferone, Diego
    Mirakhur, Beloo
    Hoffmanns, Philipp
    Houchard, Aude
    Caplin, Martyn
    Baudin, Eric
    [J]. PANCREAS, 2017, 46 (03) : 451 - 451
  • [39] Lanreotide depot/autogel (LAN) in intestinal and pancreatic neuroendocrine tumors (NETs) according to body mass index (BMI): Subgroup analyses from the CLARINET study.
    Wolin, Edward M.
    Caplin, Martyn E.
    Pavel, Marianne E.
    Cwikla, Jaroslaw B.
    Phan, Alexandria T.
    Raderer, Markus
    Sedlackova, Eva
    Cadiot, Guillaume
    Capdevila, Jaume
    Wall, Lucy
    Rindi, Guido
    Langley, Alison
    Gomez-Panzani, Edda
    Ruszniewski, Philippe B.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [40] Lanreotide autogel/depot (LAN) treatment for carcinoid syndrome (CS) symptoms: Patient-reported outcomes (PROs) from the SYMNET study.
    Ruszniewski, Philippe B.
    Caplin, Martyn E.
    Valle, Juan W.
    Lombard-Bohas, Catherine
    Poston, Graeme John
    Perros, Petros
    Holubec, Lubos
    Delle Fave, Gianfranco
    Smith, Denis Michel
    Niccoli, Patricia
    Maisonobe, Pascal
    Atlan, Philippe
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345